Quality of Life Outcomes From the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy (ATTLAS, KCSG-LU19-04) in EGFR/ALK-Mutated Non-Small-Cell Lung Cancer.
Kang Eun Joo EJ, Park Sehhoon S, Kim Tae Min TM, Han Ji-Youn JY et al.
The phase 3 ATTLAS study demonstrated that atezolizumab plus bevacizumab, carboplatin, and paclitaxel (ABCP) improved progression-free survival compared with pemetrexed-carboplatin/cisplatin (PC) in EGFR/ALK-mutated non-small-cell lung cancer after tyrosine kinase inhibitor failure. We report patient-reported quality of life (QoL) outcomes. Patients received ABCP (atezolizumab 1200 mg, bevacizumab 15 mg/kg, carboplatin AUC 5-5.5, paclitaxel 175 mg/m2) or PC (pemetrexed 500 mg/m2, carboplatin AUC 5.0, or cisplatin 70 mg/m2) every 3 weeks. QoL was assessed using EORTC QLQ-C30 and QLQ-LC13. Primary endpoints were changes in global health status/QoL (GHS/QoL) from baseline at weeks 9 and 24, and median time to deterioration (TTD; ≥ 10-point decline). Of 228 randomized patients (2:1), 146 (ABCP) and 68 (PC) completed ≥ 1 QoL assessment. Baseline GHS/QoL was comparable between arms. Early GHS and physical functioning scores were numerically lower with ABCP but stabilized by week 24, with no significant differences at week 9 (-4.66; p = 0.247) or week 24 (-7.39; p = 0.305). Toxicity-related symptoms (neuropathy, alopecia, and pain) were more frequent with ABCP, whereas cancer-related symptom improvements (cough, dyspnea, and hemoptysis) occurred in both arms without significant differences. Median TTD was 3.48 months (ABCP) versus 6.90 months (PC; p = 0.160). Despite impairment in symptoms commonly associated with chemotherapy, no significant between-group difference in overall QoL was detected between ABCP and PC. Stable GHS/QoL and improvement in cancer-related symptoms were observed alongside appropriate toxicity management. The protocol was approved by the institutional review board of Samsung Medical Center (IRB no. 2019-03-027) and participating centers (ClinicalTrials.gov identifier: NCT03991403).